Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.22M | $2.11M | $1.52M | $1.52M | $1.52M | $140M | $0.00 | $0.00 | $23.7M | $172M |
| Revenue growth | — | 72.8% | -28.0% | 0.0% | 0.0% | 9109.6% | -100.0% | — | — | 627.8% |
| Operating income | -$43.8M | -$62.0M | -$75.9M | -$57.5M | -$71.4M | $26.2M | -$152M | -$230M | -$340M | -$273M |
| Operating margin | -3587.4% | -2939.0% | -5001.7% | -3792.9% | -4708.2% | 18.8% | — | — | -1434.4% | -158.4% |
| Net income | -$44.5M | -$60.8M | -$74.0M | -$56.0M | -$73.2M | $24.9M | -$149M | -$209M | -$319M | -$285M |
| Net margin | -3645.2% | -2884.3% | -4875.5% | -3694.6% | -4822.5% | 17.8% | — | — | -1346.1% | -165.6% |
| EPS (diluted) | -$3.22 | -$2.90 | -$2.92 | -$1.84 | -$1.87 | $0.46 | -$2.46 | -$2.98 | -$3.72 | -$3.29 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$35.2M | -$47.4M | -$68.5M | -$50.6M | -$71.3M | $29.1M | -$134M | -$161M | -$275M | -$323M |
| Capital expenditures | $261K | $84.0K | $187K | — | $0.00 | $129K | $0.00 | $0.00 | $0.00 | $187K |
| Free cash flow | -$35.4M | -$47.5M | -$68.7M | — | -$71.3M | $29.0M | -$134M | -$161M | -$275M | -$323M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $23.8M | $35.2M | $33.8M | $24.6M | $115M | $222M | $74.4M | $295M | $154M | $135M |
| Total assets | $109M | $137M | $83.9M | $63.5M | $301M | $450M | $497M | $613M | $725M | $530M |
| Total liabilities | $24.9M | $32.9M | $30.9M | $31.9M | $48.4M | $41.3M | $29.8M | $58.7M | $437M | $465M |
| Shareholders' equity | $84.1M | $104M | $53.0M | $31.6M | $252M | $408M | $467M | $554M | $288M | $64.6M |
| Retained earnings | -$305M | -$366M | -$439M | -$495M | -$569M | -$544M | -$693M | -$902M | -$1.22B | -$1.51B |
| Shares (wtd avg diluted) | 18.2M | 24.4M | 24.8M | 30.5M | 41.3M | 53.6M | 60.8M | 70.4M | 85.6M | 86.6M |
Every figure is extracted from Syndax Pharmaceuticals Inc’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.